Hoth Therapeutics通过提交专利申请扩大其Ht-001药物的开发范围,重点针对药物诱发的过敏反应、放射治疗引起的皮疹以及Menin抑制剂相关的皮肤毒性反应等适应症。
Hoth Therapeutics通过提交专利申请扩大其Ht-001药物的开发范围,重点针对药物诱发的过敏反应、放射治疗引起的皮疹以及Menin抑制剂相关的皮肤毒性反应等适应症。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.